These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1386678)

  • 1. Extrapolations from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapy.
    Rojas A; Joiner MC; Denekamp J
    Radiother Oncol; 1992 Jun; 24(2):123-4. PubMed ID: 1386678
    [No Abstract]   [Full Text] [Related]  

  • 2. Carbogen and nicotinamide: expectations too high?
    Brown JM
    Radiother Oncol; 1992 Jun; 24(2):75-6. PubMed ID: 1386679
    [No Abstract]   [Full Text] [Related]  

  • 3. Carbogen and nicotinamide: expectations too high? (response to J. Martin Brown).
    Horsman MR
    Radiother Oncol; 1992 Jun; 24(2):121-2. PubMed ID: 1386677
    [No Abstract]   [Full Text] [Related]  

  • 4. Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time.
    Chaplin DJ; Horsman MR; Siemann DW
    Br J Cancer; 1993 Aug; 68(2):269-73. PubMed ID: 8347481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitisation in normal tissues with oxygen, carbogen or nicotinamide: therapeutic gain comparisons for fractionated x-ray schedules.
    Rojas A; Vojnovic B; Johns H; Joiner MC; Martindale C; Fowler JF; Denekamp J
    Radiother Oncol; 1996 Apr; 39(1):53-64. PubMed ID: 8735494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
    Dorie MJ; Menke D; Brown JM
    Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitization of SCCVII tumours and normal tissues by nicotinamide and carbogen: analysis by micronucleus assay.
    Ono K; Masunaga S; Akuta K; Akaboshi M; Abe M
    Radiother Oncol; 1993 Aug; 28(2):162-7. PubMed ID: 8248558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen and nicotinamide.
    Droller MJ
    J Urol; 2000 May; 163(5):1600. PubMed ID: 10798919
    [No Abstract]   [Full Text] [Related]  

  • 9. Is hyperbaric oxygen more effective than carbogen/nicotinamide in tumor radiation response?
    Hartmann KA; Van der Kleij AJ; Schneider CJ; Sminia P
    Radiat Res; 1997 Nov; 148(5):523-5. PubMed ID: 9355875
    [No Abstract]   [Full Text] [Related]  

  • 10. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) in high grade malignant gliomas.
    Lambin P; Poortmans P; Menten J; Hamers HP
    Radiother Oncol; 1997 Jun; 43(3):324. PubMed ID: 9215796
    [No Abstract]   [Full Text] [Related]  

  • 11. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer.
    Kaanders JH; Pop LA; Marres HA; Liefers J; van den Hoogen FJ; van Daal WA; van der Kogel AJ
    Radiother Oncol; 1998 Aug; 48(2):115-22. PubMed ID: 9783882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of combined nicotinamide and carbogen treatments in human tumour xenografts: oxygenation and tumour control studies.
    Stüben G; Stuschke M; Knühmann K; Horsman MR; Sack H
    Radiother Oncol; 1998 Aug; 48(2):143-8. PubMed ID: 9783885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing.
    Siemann DW; Horsman MR; Chaplin DJ
    Radiother Oncol; 1994 May; 31(2):117-22. PubMed ID: 8066190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARCON.
    Rojas A
    Strahlenther Onkol; 1996 Nov; 172 Suppl 2():34-5. PubMed ID: 8946047
    [No Abstract]   [Full Text] [Related]  

  • 15. ARCON--current status: summary of a workshop on preclinical and clinical studies.
    Denekamp J; Fowler JF
    Acta Oncol; 1997; 36(5):517-25. PubMed ID: 9292749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiotherapy and chemotherapy with or without carbogen and nicotinamide in inoperable biopsy-proven glioblastoma multiforme.
    Simon JM; Noël G; Chiras J; Hoang-Xuan K; Delattre JY; Baillet F; Mazeron JJ
    Radiother Oncol; 2003 Apr; 67(1):45-51. PubMed ID: 12758239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential for improving radiotherapy outcome by improving the oxygen supply to solid tumours.
    Denekamp J; Waites A
    Strahlenther Onkol; 1996 Nov; 172 Suppl 2():22-3. PubMed ID: 8946041
    [No Abstract]   [Full Text] [Related]  

  • 18. Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
    Hoskin PJ; Saunders MI; Phillips H; Cladd H; Powell ME; Goodchild K; Stratford MR; Rojas A
    Br J Cancer; 1997; 76(2):260-3. PubMed ID: 9231929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbogen and nicotinamide in locally advanced bladder cancer: early results of a phase-III randomized trial.
    Hoskin PJ; Rojas AM; Saunders MI; Bentzen SM; Motohashi KJ;
    Radiother Oncol; 2009 Apr; 91(1):120-5. PubMed ID: 18992952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of perfusion enhancement after administration of nicotinamide and carbogen in patients with glioblastoma: a 99mTc-HMPAO SPECT study.
    Hulshof MC; Rehmann CJ; Booij J; van Royen EA; Bosch DA; González González D
    Radiother Oncol; 1998 Aug; 48(2):135-42. PubMed ID: 9783884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.